ONCE A MARKET DARLING, COCHLEAR’S CHRIS ROBERTS NOW HAS A HARD TIME GETTING HIS MESSAGE THROUGH TO INVESTORS AND ANALYSTS.
Hearing implant company Cochlear had long been a market darling, but these e days chief executive Chris s Roberts has a hard time getting his message across. s.
Chris Roberts was typically self-assured when he arrived at the Sydney offices of global investment bank UBS for its annual healthcare conference. It was themiddle of June and the 100 or so audience members – mostly fundmanagers and high net worth investors – were understandably keen to hear what the Cochlear boss had to say about the critical juncture his company was facing.
A global success story, Cochlear is a rarity in Australia’s corporate history. Based on the pioneering research of surgeon Graeme Clark, the company has evolved over 30 years to be a world expert in implanted hearing devices. Headquartered in Sydney, it has operations in more than 20 countries and has implanted more than 300,000 devices worldwide, with